Management of primary immune thrombocytopenia. A comparison between two historical cohorts

Sandra Fernández-Plaza1, Jesús González de Pablo1, Eva Gálvez1

  • 1Hospital Infantil Universitario Niño Jesús, Madrid, Spain.

Anales De Pediatria
|July 11, 2021
PubMed

Insights

Management of childhood primary immune thrombocytopenia has evolved, with updated guidelines leading to reduced steroid doses and hospital stays. Younger children and those with prior infections show better recovery chances.

Area of Science:

  • Pediatric Hematology
  • Immunology
  • Clinical Research

Background:

  • Primary immune thrombocytopenia (ITP) management in children has seen recent changes.
  • This study reviews ITP patient characteristics and outcomes at a children's hospital.
  • Care changes were analyzed comparing patients diagnosed before and after 2011 SEHOP guidelines.

Purpose of the Study:

  • To evaluate changes in pediatric primary immune thrombocytopenia management post-2011 guidelines.
  • To identify patient characteristics influencing cure probability.
  • To assess the impact of updated guidelines on treatment outcomes.

Main Methods:

  • Retrospective review of a primary immune thrombocytopenia patient cohort.
  • Analysis of clinical data from 235 pediatric patients.
  • Statistical analysis using SPSS Statistics 22.0.

Main Results:

  • Features like age (<5 years) and prior infection history influenced cure probability.
  • Post-2011, steroid doses (1st month/year) and initial hospital admission duration significantly decreased.
  • Splenectomy rates were significantly reduced.

Conclusions:

  • Updated ITP care since 2011 involves lower steroid doses and shorter hospitalizations.
  • Reduced splenectomies did not worsen bleeding or clinical outcomes.
  • Younger age and prior infection correlate with higher recovery rates in pediatric ITP.
Abstract